Novel Use of Sacituzumab Govitecan with and without Pembrolizumab in Patients with Hormone Receptor-Positive (HR+) / HER2- Metastatic Breast Cancer (Phase II)

Breast Cancer
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute


This trial is testing the effectiveness, safety, and tolerability of the novel combination of two drugs (sacituzumab govitecan and pembrolizumab) for patients diagnosed with HR+ / HER2- metastatic breast cancer. Patients will be assigned into two groups: Group 1 will receive sacituzumab govitecan and pembrolizumab; Group 2 will receive sacituzumab govitecan only. This will allow the researchers to see if the addition of pembrolizumab makes the treatment more effective, safe, and tolerable. If the study is successful, it could lead to a new life-prolonging therapy for patients with HR+/HER2- metastatic breast cancer.